Press Release

Give Us The Scoop

Do you have a news tip on AIML or related information or photos about a news story to pass along to our team? Send a newstip or email us at

Send us a blog-pitch Email: to pitch an idea for a blog post to the AI ML Blog Team

ConvertibleCAR-T, a highly adaptable CAR-T platform to fight HIV

One potential approach to achieving a functional HIV cure is to first reduce the size of the HIV reservoir and then engineer an immune response that can effectively control the shrunken reservoir in the absence of antiretroviral therapy. MicAbodies, comprised of full-length broadly neutralizing HIV antibodies coupled to a mutated ligand, selectively engage a mutant receptor that has been engineered as a chimeric antigen receptor (CAR) and expressed on CD8 T cells (convertibleCAR-T cells). The HIV-specific MicAbodies and the convertibleCAR-T cells can detect and eliminate HIV infected cells. The modularity of the convertibleCAR-T cell system allows multiplexing with several anti-HIV antibodies and yields greater breadth and control, thus making this platform a promising tool for attacking the latent HIV reservoir.

Creative Biolabs invites Dr. Eytan Herzig, a Staff Research Scientist at the University of California, San Francisco, to share his profound insights on the principles and opportunities of innovative convertibleCAR-T platform in HIV cure.

During this webinar, we will discuss:

  • The potential approach to achieve a functional HIV cure
  • How does convertibleCAR-T detect and eliminate HIV infected cells?
  • The performance of the convertibleCAR-T cells ex vivo and in vivo
  • ConvertibleCAR-T cells advantages over conventional CAR-T cells
Eytan Herzig, Ph.D.
Staff Research Scientist
Gladstone Center for HIV Cure Research
University of California, San Francisco

Date: June 4th, 2020
Time: 3:00 p.m. EDT | 12:00 p.m. PDT
Registration Coming Soon

Speaker Bio

Dr. Eytan Herzig is a Staff Research Scientist in the Gladstone Center for HIV Cure Research, where he leads the use of new technologies to fight HIV. After completing his Ph.D. education at the Tel Aviv University, he worked as a postdoctoral fellow at Tel Aviv University and at Gladstone.

This email address is being protected from spambots. You need JavaScript enabled to view it.


© copyright 2017 All Rights Reserved.

A Product of HunterTech Ventures